Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.

Academic Article


  • BACKGROUND: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-na├»ve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. METHODS: Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed. RESULTS: Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events. CONCLUSION: Week 96 data confirm week 48 observations in MERIT.
  • Published In


  • Adolescent, Adult, Aged, Anti-HIV Agents, Benzoxazines, CCR5 Receptor Antagonists, Cyclohexanes, Drug Therapy, Combination, Female, HIV Fusion Inhibitors, HIV Infections, HIV-1, Humans, Lamivudine, Male, Maraviroc, Middle Aged, Treatment Outcome, Triazoles, Zidovudine
  • Digital Object Identifier (doi)

    Author List

  • Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J
  • Start Page

  • 125
  • End Page

  • 132
  • Volume

  • 11
  • Issue

  • 3